Huntington National Bank’s Serina Therapeutics SER Stock Holding History

Huntington National Bank’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1	Closed	–	–	1841
2019 Q1	$0	Buy	+1	New	+$146	﹤0.01%	1834

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Huntington National Bank's SER Position: Q2 2019 in Review

Huntington National Bank sold out of Serina Therapeutics (SER) in Q2 2019, closing a stake of 1 share.

Huntington National Bank first reported a position in SER in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 51 funds tracked by Wall St. Rank hold SER as of Q2 2019.

Huntington National Bank reported no remaining Serina Therapeutics position as of Q2 2019 after selling out during the quarter.
Huntington National Bank sold 1 Serina Therapeutics share in Q2 2019.
Huntington National Bank first reported a position in Serina Therapeutics in Q1 2019 and held it in 1 quarter.
Huntington National Bank's Serina Therapeutics position peaked at $0 in Q1 2019.
51 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2019.

Based on Huntington National Bank's 13F filing for Q2 2019, filed 23 Jul 2019.